What happened with LQDA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Liquidia Corporation sells medicines for patients with high blood pressure in the blood vessels of the lungs. Most revenue comes from U.S. sales of YUTREPIA, a dry-powder form of treprostinil delivered through an inhaler. It is FDA-approved for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Sales depend on doctors prescribing it, patients using it and insurers covering treatment; the company has no products approved for sale outside the United States.
Liquidia also promotes Sandoz’s generic Treprostinil Injection for pulmonary arterial hypertension in the United States and receives a share of its net profits. Sandoz holds the drug’s approval and handles manufacturing, supply and distribution. Sales for use under the skin are constrained because the required CADD-MS 3 pumps are no longer manufactured or supported, and specialty pharmacies limit new patients until a replacement is available.
YUTREPIA supply relies on sole suppliers: LGM Pharma for its active ingredient, Plastiape for its inhaler and Lonza Tampa for encapsulation and packaging. Continued sales also depend on the outcome of United Therapeutics’ lawsuits, which seek restrictions that could remove YUTREPIA from the market or remove its interstitial-lung-disease indication.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Liquidia’s results depend chiefly on YUTREPIA adoption and reliable supply from sole providers including Lonza, while Sandoz supplies its smaller injectable-treprostinil profit-sharing business.
United Therapeutics competes for Liquidia’s pulmonary arterial hypertension (PAH) and interstitial-lung-disease-associated pulmonary hypertension (PH-ILD) patients with inhaled Tyvaso DPI and nebulized Tyvaso, while its Remodulin competes with the generic injection Liquidia promotes. Tyvaso sales show the strength of the direct competition facing YUTREPIA.
MannKind earns money from YUTREPIA’s direct rival: United Therapeutics pays it to manufacture and supply inhaled Tyvaso DPI, and it receives royalties on the drug’s net sales. Its Tyvaso DPI royalty revenue gives Liquidia holders a view of competing product sales.
Insmed could challenge Liquidia’s YUTREPIA with once-daily inhaled treprostinil palmitil, now in pivotal studies for the same PAH and PH-ILD patients. Watch whether the trials show efficacy and safety similar to YUTREPIA with less frequent dosing—the combination Liquidia warns could take market share rapidly.
Merck’s injectable PAH treatment Winrevair could shrink the market for Liquidia’s YUTREPIA and L606 if used earlier in treatment. Watch whether it moves ahead of prostacyclin therapies, rather than its usual place after them.
Johnson & Johnson offers PAH patients alternatives to Liquidia’s therapies through oral Uptravi and inhaled Ventavis, both acting on the prostacyclin pathway. Twice-daily Uptravi brings the perceived convenience of oral treatment, while Ventavis use has dwindled because it requires nebulizer treatment six to nine times daily.
Gossamer Bio, Inc. is developing inhaled seralutinib with Chiesi for Liquidia’s PAH and PH-ILD markets, but its potential competition is uncertain. Its Phase 3 PAH trial missed the six-minute-walk-distance primary endpoint in February 2026, making the next development decision more relevant to Liquidia than any prospective sales.
Insmed, Inc. earningsINSM
Insmed’s report may clarify progress on its once-daily inhaled treatment, a potential future rival to Liquidia for PAH and PH-ILD patients.
Look for updates on pivotal-trial progress and plans; research spending or losses do not establish that the treatment works. If the program advances toward testing whether efficacy and safety can approach existing inhaled therapies with less frequent dosing, future competition for YUTREPIA becomes more concrete. A setback or stalled program would make that threat less immediate, not erase it.
Liquidia Corporation earningsThis company
Liquidia’s report will show whether YUTREPIA sales are growing fast enough relative to selling costs and continuing losses to support the business.
Read net YUTREPIA product sales alongside selling, general and administrative expense, then check the operating loss. Sales growing faster than that expense while the loss narrows would show new revenue beginning to absorb commercialization costs. Sluggish sales growth with rising expense would leave losses weighing on cash and further development. The question is whether growth is starting to make the business more sustainable.
United Therapeutics Corp earningsUTHR
United Therapeutics’ report will show how Tyvaso sales are holding up with PAH and PH-ILD patients, revealing the strength of the direct competition facing YUTREPIA.
Look at sales tied to Tyvaso. Strong sales would show that an established rival continues to attract the same PAH and PH-ILD patients, making it harder for YUTREPIA to win prescriptions and patients. Weaker sales could mean less pressure from that rival, but would not show that patients switched to YUTREPIA. The report gauges the incumbent’s strength in the shared patient market, not Liquidia’s market share.
